Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

The post Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder? appeared first on 24/7 Wall St.. Quick Read AbbVie (ABBV) received a Buy initiation from Canaccord with a $262 price target (18% upside from $205), backed by 2025 revenue of $61.16B (+9% YoY), immunology franchise revenue of $8.63B (+18%), and 2026 EPS guidance of $14.37-$14.57 showing visible earnings acceleration. Canaccord’s bull…